Ispire Technology (ISPR) vs MediWound (MDWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MediWound (MDWD) has outperformed Ispire Technology (ISPR) over the past year, losing 20.3% versus a loss of 43.6%. MediWound is the larger company by market cap ($195.6 million vs $71.1 million), about 2.8 times the size. Ispire Technology converts more of its revenue into profit, with a net margin of -34.6% versus -140.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ISPR | MDWD |
|---|---|---|
| Share price | $1.23 | $13.59 |
| Market cap | $71.05M | $195.56M |
| 1-day change | -3.15% | +0.37% |
| YTD return | -56.07% | -26.38% |
| 1-year return | -43.58% | -20.34% |
| 5-year return | — | -25.04% |
| EPS (TTM) | $-0.64 | $-2.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $96.01M | $16.96M |
| Revenue growth (YoY) | -24.69% | -16.14% |
| Net income (latest FY) | $-33.20M | $-23.88M |
| Gross margin | 12.81% | 19.19% |
| Operating margin | -33.95% | -148.98% |
| Net margin | -34.58% | -140.80% |
| 52-week high | $3.87 | $19.70 |
| 52-week low | $1.01 | $11.80 |
| Distance from 52-week high | -68.22% | -31.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +298.37% | +118.32% |
| Average volume | 20.51K | 125.80K |
| Shares outstanding | 57.77M | 14.39M |
| Employees | 88 | 121 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MediWound is about 2.8 times larger than Ispire Technology by market value ($195.56M vs $71.05M).
- MDWD has outperformed ISPR by 23.2 percentage points over the past year.
- Ispire Technology is more profitable, keeping -34.6 cents of every revenue dollar as net income versus -140.8 cents for MediWound.
- MediWound grew revenue faster in its latest fiscal year (-16.14% vs -24.69%).
About Ispire Technology
ISPR stock →Ispire Technology Inc. researches, develops, designs, commercializes, sells, markets, and distributes e-cigarettes and cannabis vaping products worldwide under the Aspire brands.
Health Care · Medicinal Chemicals and Botanical Products · 88 employees
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
ISPR vs MDWD FAQ
Which is bigger, Ispire Technology or MediWound?
MediWound (MDWD) is larger, with a market capitalization of $195.56M compared with $71.05M for Ispire Technology (ISPR).
Which stock has performed better over the past year, ISPR or MDWD?
MDWD returned -20.34% over the past 12 months, compared with -43.58% for ISPR (price return, excluding dividends). Past performance does not predict future results.
Are Ispire Technology and MediWound in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.